Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,769
Recruiting: 1,010
Ph III recruiting: 99
Growth YoY: −1.7%
Industry share: 19%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 35.6%
Trials / 1,000 deaths: 75 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,348)

clinicaltrialsPublishedShowing 1–15 of 15 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06205290	A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies	withdrawn	Phase 3	0	Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY	11	Apr 2, 2024	clinicaltrials
NCT00488605	H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis	withdrawn	Phase 3	0	University of New Mexico